



25/C
goiga
4.11.3

Atty. Docket No.: 2312/2085B

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Raghuram Kalluri
Serial No.: 09/543,371
Filed: April 4, 2000
Entitled: ANTI-ANGIOGENIC PROTEINS
AND FRAGMENTS AND
METHODS OF USE THEREOF

Examiner J. Roark
Group Art Unit: 1644
Conf. No.: 6148

CERTIFICATE OF MAILING UNDER 37 CFR 1.10

I hereby certify that the paper (and any paper or fee referred to as being enclosed) is being deposited with the United States Postal Service using Express Mail to Addressee Service, under 37 C.F.R. Section 1.10, **Express Mail Label No. EL928102083US** on this date, **April 11, 2003**, postage prepaid, in an envelope addressed to Box: RCE, Commissioner for Patents, Washington, D.C. 20231.

Brenda M. Woods

Name of Person Mailing Paper

Brenda M. Woods

Signature of Person Mailing Paper

TECH CENTER 1600/2900

APR 15 2003

RECEIVED

Box: RCE
Commissioner for Patents
Washington, D.C. 20231

Preliminary Amendment

Sir:

Applicant respectfully request entry of the Amendment After Final filed September 11, 2002. A Notice of Appeal was filed September 11, 2002. In lieu of an Appeal Brief, a Request for Continued Examination (RCE) and Petition for Extension of Five (5) Months Time to maintain the pendency of the application up to and including April 11, 2003.

Please amend the application as follows:

In the Claims

Please cancel claim 8 without prejudice.

Please amend claims 1 and 3 as follows:

1. (Twice amended) A composition comprising a non-Goodpasture fragment of $\alpha 3(\text{IV})$ NC1 domain and comprising amino acid residues 185-203 of SEQ ID NO:10, having at least one of the following activities:
 - (a) an ability to bind $\alpha \nu \beta_3$ integrin; and
 - (b) an ability to inhibit proliferation of tumor cells; anda pharmaceutically-acceptable carrier.
3. (Amended) The composition of Claim 2, wherein the tumor cells are melanoma cells.